title: Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model.
abstract: Antimicrobial therapy of infections with Staphylococcus aureus can pose a challenge due to slow response to therapy and recurrence of infection. These treatment difficulties can partly be explained by intracellular survival of staphylococci, which is why the intracellular activity of antistaphylococcal compounds has received increased attention within recent years. The intracellular activity of plectasin, an antimicrobial peptide, against S. aureus was determined both in vitro and in vivo. In vitro studies using THP-1 monocytes showed that some intracellular antibacterial activity of plectasin was maintained (maximal relative efficacy [E(max)], 1.0- to 1.3-log reduction in CFU) even though efficacy was inferior to that of extracellular killing (E(max), >4.5-log CFU reduction). Animal studies included a novel use of the mouse peritonitis model, exploiting extra- and intracellular differentiation assays, and assessment of the correlations between activity and pharmacokinetic (PK) parameters. The intracellular activity of plectasin was in accordance with the in vitro studies, with an E(max) of a 1.1-log CFU reduction. The parameter most important for activity was fC(peak)/MIC, where fC(peak) is the free peak concentration. These findings stress the importance of performing studies of extra- and intracellular activity since these features cannot be predicted from traditional MIC and killing kinetic studies. Application of both the THP-1 and the mouse peritonitis models showed that the in vitro results were similar to findings in the in vivo model with respect to demonstration of intracellular activity. Therefore the in vitro model was a good screening model for intracellular activity. However, animal models should be applied if further information on activity, PK/pharmacodynamic parameters, and optimal dosing regimens is required.
authors.affiliation: Novozymes A/S, Anti-Infective Discovery, Krogshøjvej 36, DK-2880 Bagsvaerd, Denmark. kbri@novozymes.com
authors.forename: Karoline Sidelmann
authors.initials: KS
authors.lastname: Brinch
authors.forename: Anne
authors.initials: A
authors.lastname: Sandberg
authors.forename: Pierre
authors.initials: P
authors.lastname: Baudoux
authors.forename: Françoise
authors.initials: F
authors.lastname: Van Bambeke
authors.forename: Paul M
authors.initials: PM
authors.lastname: Tulkens
authors.forename: Niels
authors.initials: N
authors.lastname: Frimodt-Møller
authors.forename: Niels
authors.initials: N
authors.lastname: Høiby
authors.forename: Hans-Henrik
authors.initials: HH
authors.lastname: Kristensen
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D051379:Mice; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D009000:Monocytes / Q000382:microbiology*; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D010538:Peritonitis / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*
chemical_list: D010455:Peptides; C504857:plectasin